Jasper Therapeutics Stock Declines Following Early Trial Results for Chronic Urticaria Treatment

Investing.com -- The stock value of the pharmaceutical company Jasper Therapeutics has significantly dropped, with shares declining by up to 52% in pre-market trading. This sharp decline came after the company announced preliminary results from an early-stage trial of its experimental treatment for chronic urticaria. The results did not meet investor expectations.

The study, known as BEACON Phase 1b/2a, focused on the efficacy of briquilimab in treating chronic spontaneous urticaria (CSU), a skin condition commonly referred to as chronic hives, in adults.

"We believe that, along with the favorable safety profile provided by our optimal biological dosing approach, briquilimab has the potential to be a leading therapeutic option for CSU patients," the company stated in a press release.